SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMXX - GENEMAX CORP
ISON 0.00May 16 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: StockDung2/25/2008 6:14:16 PM
   of 978
 
TapImmune (formerly GeneMax) taps into the immune system to take out autoimmune disorders and transplant tissue rejection. Its research is primarily focused on the cells' TAP system that triggers an immune system response. The TAP system shuts down in many cancer tumor cells, but the company is developing a vaccine to restore the immune function. TAPImmune's other potential products include a Peptide Transfer Assay (IPTA) technology that identifies compounds which modulate the immune system. It has also licensed a technology to screen and select potential drugs to regulate immune responses. The company in 2007 underwent a reverse merger with its TapImmune subsidiary, after which the GeneMax name was retired

. biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext